<DOC>
	<DOCNO>NCT00738257</DOCNO>
	<brief_summary>The purpose study evaluate effect Pamidronate bone mineral density loss fracture rate 2 year , post renal-transplant subject Ciclosporin A glucocorticoid base immunosuppressive regimen .</brief_summary>
	<brief_title>A Prospective , Multicentre , Open-label Randomised Controlled Study Investigate Effectiveness Pamidronate Prevention Bone Loss de Novo Renal Transplant Patients .</brief_title>
	<detailed_description />
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>1 . First second kidney transplant recipient , age 1875 year , PTH &gt; 150 pg/ml 2 . De novo patient schedule receive ciclosporin A prednisolone base immunosuppression . 1 . Previous current bone disease unrelated end stage renal failure . 2 . Patients PTH &lt; 150pg/ml may risk adynamic bone disease . 3 . Treatment time bisphosphonate . 4. d. Calcitonin treatment previous month . 5 . Malignancy ( current history within last 5 year ) 6 . Pregnancy lactation , woman childbearing potential unwilling use effective form contraception 12 month duration study . Protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Renal</keyword>
	<keyword>transplant ,</keyword>
	<keyword>pamidronate ,</keyword>
	<keyword>ciclosporin ,</keyword>
	<keyword>Ciclosporin A ,</keyword>
	<keyword>steroid ,</keyword>
	<keyword>bone mineral density ,</keyword>
	<keyword>fracture rate</keyword>
	<keyword>immunosuppressive</keyword>
	<keyword>regimen</keyword>
</DOC>